Cannabidivarin (cbdv) Drug Interactions, Uses, Effectiveness, Safety & More
What is this page for?
First and foremost: how Cannabidivarin (cbdv) interacts with medications. The heart of this page is the interaction list — every drug Cannabidivarin (cbdv) is known to interact with, and how serious each one is.
But these pages have grown well beyond that into a full monograph — what Cannabidivarin (cbdv) is, what people use it for and how strong the evidence is, its safety and side effects, and answers to the questions we’re asked most — written and reviewed by the clinical staff at HelloPharmacist. It’s educational information from our licensed clinical databases, not medical advice, and we don’t sell or endorse products. Our editorial policy
Check Cannabidivarin (cbdv) against your medication
Add one medicationDrugs that interact with Cannabidivarin (cbdv)
0 medications have a known interaction with Cannabidivarin (cbdv), graded by severity. Select any drug for the full evidence-based detail.
We don’t currently list any known drug interactions for Cannabidivarin (cbdv). This doesn’t guarantee none exist — always confirm with your pharmacist before combining supplements with your medications.
What Severity, Likelihood & Evidence Mean
Severity — How Serious It Can Be
- Major. Clinically significant; generally best avoided, or used only under direct professional supervision.
- Moderate. May need monitoring, a dose adjustment, or separating the times you take each one.
- Minor. Generally not clinically significant, but still worth noting and mentioning to your pharmacist.
- No known interaction. Checked against our sources with nothing documented — not the same as proven safety.
Likelihood — How Well It’s Documented
- Likely. Well-controlled human studies have demonstrated the likely existence of this interaction
- Probable. Interaction has not been documented in well-controlled studies, however, the interaction has been demonstrated in some small human studies or in controlled animal studies in conjunction with multiple case reports.
- Possible. Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists
- Unlikely. Interaction has been demonstrated in animal or in lab research but has been shown not to occur in humans.
Where This Data Comes From
- Interaction records are evidence-graded and sourced from the Natural Medicines database (TRC Healthcare), the same reference used by pharmacists and hospitals.
- Each drug listed above links to the full report for that exact Cannabidivarin (cbdv) combination — clinical detail, likelihood, evidence level, and citations.
- Content is reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.
Cannabidivarin (cbdv): Uses, Safety & Side Effects
Cannabidivarin (CBDV) is a non-intoxicating compound found in cannabis that is being studied mainly for epilepsy and certain neurodevelopmental conditions. The research is still early, mostly from laboratory and animal studies plus small human trials, so it is not an approved or proven treatment. Talk to your pharmacist or doctor before trying any CBDV product.
- Family
- Cannabaceae
- Part used
- Compound derived from the flowers and leaves of the cannabis plant
- Common forms
- Oils, tinctures, isolates, and research-grade formulations
- Epilepsy and seizures
- Autism spectrum disorder
- Rett syndrome
- Fragile X syndrome
- Nausea
- Anxiety
Popular and traditional uses — not proof it works. See “Uses & effectiveness” below for the evidence.
Human safety data are very limited, so long-term effects are not well understood.
Insufficient reliable information available; avoid using.
Read the full pregnancy detailInsufficient reliable information available; avoid using.
Read the full breastfeeding detailPregnancy & breastfeeding ratings are from Natural Medicines (Therapeutic Research Center). Safety guidance is general; always confirm with your pharmacist or doctor for your situation.
Overview
Cannabidivarin (CBDV) is a naturally occurring compound found in the cannabis plant. It is closely related to cannabidiol (CBD) and, like CBD, it is non-intoxicating — meaning it does not cause the "high" linked to THC.
CBDV is usually present in cannabis in small amounts. It is sold in some oils, tinctures, and isolate products, but it is much less common than CBD. Most of the attention around CBDV comes from research into seizures and brain-related conditions rather than from long traditional use.
Because CBDV is a relatively new area of study, products on the market are not well standardized, and quality can vary a lot between brands.
How it works
CBDV is a cannabinoid, part of the same family of compounds as CBD and THC. Unlike THC, it does not strongly activate the brain receptors that cause intoxication.
Researchers think CBDV may act on certain ion channels in the body, including TRP channels, which help control pain, temperature sensing, and possibly the activity of nerve cells. This is one proposed reason it has been studied for seizures.
It is important to know that most of what we understand about how CBDV works comes from laboratory and animal research. The way it behaves in the human body is still not fully mapped out.
Does Cannabidivarin (cbdv) work?
How to read these evidence grades
Natural Medicines’ 7-point scale. We show each rating’s label word-for-word.
Possibly Ineffective Epilepsy
Oral cannabidivarin does not seem to reduce the incidence of focal seizures.
Also studied for 10 conditions — evidence insufficient to rate
Insufficient Reliable Evidence To Rate Autism spectrum disorder
Although there is interest in using oral cannabidivarin for autism spectrum disorder, there is insufficient reliable information about the clinical effects of cannabidivarin for this condition.
Insufficient Reliable Evidence To Rate Crohn disease
Although there is interest in using oral cannabidivarin for Crohn disease, there is insufficient reliable information about the clinical effects of cannabidivarin for this condition.
Insufficient Reliable Evidence To Rate Duchenne muscular dystrophy
Although there is interest in using oral cannabidivarin for Duchenne muscular dystrophy, there is insufficient reliable information about the clinical effects of cannabidivarin for this condition.
Insufficient Reliable Evidence To Rate Fragile X syndrome
Although cannabidivarin is under investigation for use in Fragile X syndrome and has been granted an orphan designation by the European Medicines Agency and US Food and Drug Administration (FDA) for this purpose, there is insufficient reliable information available about its clinical effects.
Insufficient Reliable Evidence To Rate Multiple sclerosis (MS)
Although there is interest in using oral cannabidivarin for MS, there is insufficient reliable information about the clinical effects of cannabidivarin for this condition.
Insufficient Reliable Evidence To Rate Nausea and vomiting
Although there is interest in using oral cannabidivarin for nausea, there is insufficient reliable information about the clinical effects of cannabidivarin for this condition.
Insufficient Reliable Evidence To Rate Neuropathic pain
There is limited evidence on the oral use of cannabidivarin in patients with neuropathic pain associated with HIV.
Insufficient Reliable Evidence To Rate Prader-Willi Syndrome (PWS)
Although there is interest in using oral cannabidivarin for PWS, there is insufficient reliable information about the clinical effects of cannabidivarin for this condition.
Insufficient Reliable Evidence To Rate Rett syndrome
There is limited evidence on the oral use of cannabidivarin in patients with Rett syndrome.
Insufficient Reliable Evidence To Rate Ulcerative colitis
Although there is interest in using oral cannabidivarin for ulcerative colitis, there is insufficient reliable information about the clinical effects of cannabidivarin for this condition.
Source & disclaimer. Effectiveness ratings and evidence summaries are provided by Natural Medicines (Therapeutic Research Center) and shown as licensed. Where Natural Medicines hasn’t rated a use, HelloPharmacist’s pharmacists may add their own reviewed rating and evidence (each such entry is labeled). This is educational information, not medical advice — talk with your pharmacist or doctor before starting, stopping, or changing a supplement.
Safety & precautions
Because CBDV has mostly been tested in small studies, its overall safety profile in people is not well established. We do not have good information on long-term use.
People with liver problems, those taking multiple medications, older adults, and anyone with a serious health condition should be especially careful and speak with a healthcare provider first.
Pregnancy and breastfeeding: There is not enough safety data, so CBDV should be avoided if you are pregnant, trying to become pregnant, or breastfeeding. Cannabis-derived compounds in general are not recommended during these times.
Also keep in mind that supplements are not tightly regulated, so a product may not contain the amount of CBDV listed on the label, and it may contain other cannabinoids or contaminants.
Side effects
Because human studies are limited, the full range of side effects is not well known. Based on related cannabinoids and early research, possible effects may include tiredness, stomach upset, diarrhea, and changes in appetite.
Some cannabinoids can affect the liver, so changes in liver function are possible, especially at higher doses. If you notice yellowing of the skin or eyes, dark urine, severe stomach pain, or unusual fatigue, stop using it and seek medical care.
Stop and talk to a doctor right away if you have any signs of an allergic reaction, such as rash, swelling, or trouble breathing.
Cannabidivarin (cbdv): Reported Adverse Effects
Documented safety reports on Cannabidivarin (cbdv) from the evidence-graded Natural Medicines (TRC Healthcare) database, shown word-for-word from the licensed record.
There is currently a limited amount of information on the tolerability and adverse effects of oral cannabidivarin.
Most Common Adverse Effects:
Orally: Abdominal pain, diarrhea, dizziness, headache, nausea, rash, somnolence.
Serious Adverse Effects (Rare):
Orally: Acute kidney failure and elevated liver transaminases at a dose of 800 mg twice daily.
Cluster headache Neurologic/CNS
Orally, cannabidivarin has been associated with dizziness, somnolence, and headache. Ataxia, confusion, and dysarthria have been reported in one patient in a clinical trial who had been taking cannabidivarin 800 mg twice daily for 30 days. This patient also experienced other symptoms of intoxication, including arterial hypotension, nystagmus, diplopia, and elevated liver transaminases. In children with Rett syndrome, tremor, forward lean, and hand contortion occurred in one patient, and a lateral truncal tilt to the right in two.
- Brodie MJ, Czapinski P, Pazdera L, et al. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res 2021;6(6):528-536.
- Hurley EN, Ellaway CJ, Johnson AM, et al. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia 2022;63(7):1736-1747.
Diarrhea Gastrointestinal
Orally, cannabidivarin has been associated with diarrhea, nausea, and abdominal pain. Drooling has been reported in one child with Rett syndrome.
- Brodie MJ, Czapinski P, Pazdera L, et al. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res 2021;6(6):528-536.
- Hurley EN, Ellaway CJ, Johnson AM, et al. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia 2022;63(7):1736-1747.
Hypotension Cardiovascular
Orally, arterial hypotension has been reported in one patient in a clinical trial who had been taking cannabidivarin 800 mg twice daily for 30 days. This patient also experienced other symptoms of intoxication, including severe ataxia, nystagmus, diplopia, dysarthria, mild confusion, and elevated liver transaminases.
Hypotension Ocular/Otic
Orally, diplopia and nystagmus have been reported in one patient in a clinical trial who had been taking cannabidivarin 800 mg twice daily for 30 days. This patient also experienced other symptoms of intoxication, including severe ataxia, arterial hypotension, dysarthria, mild confusion, and elevated liver transaminases.
Myasthenia gravis Hepatic
Orally, elevated liver transaminases have been reported in a small number of patients taking cannabidivarin 800 mg twice daily in conjunction with various antiepileptic medications. Transient elevated liver transaminases have also occurred in children with Rett syndrome taking cannabidivarin 10 mg/kg daily.
- Brodie MJ, Czapinski P, Pazdera L, et al. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res 2021;6(6):528-536.
- Hurley EN, Ellaway CJ, Johnson AM, et al. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia 2022;63(7):1736-1747.
Myasthenia gravis Renal
Orally, azotemia and acute kidney failure have been reported in one patient in a clinical trial who had been taking cannabidivarin 800 mg twice daily for 32 days. Kidney failure resolved after treatment discontinuation.
Myasthenia gravis Dermatologic
Orally, cannabidivarin 800 mg twice daily has been associated with maculopapular rash. The rash resolved with discontinuation of cannabidivarin.
Adverse-effects data: Natural Medicines, Therapeutic Research Center
Dosing
There is no established standard dose for CBDV. The amounts used in research studies were chosen for those specific trials and are not the same as general supplement guidance.
If you choose to use a CBDV product, follow the directions on the product label and start low. Because product strength and quality vary widely, it is wise to choose a brand that provides third-party testing.
Always check with a pharmacist or doctor before starting CBDV, especially if you take other medicines or have a health condition.
Cannabidivarin (cbdv) & Pregnancy
Cannabidivarin (cbdv) & Breastfeeding
© 2026 Therapeutic Research Center
Pregnancy & lactation ratings: Natural Medicines, Therapeutic Research Center
References & further reading
The 4 references that drive our Cannabidivarin (cbdv) monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.
- European Medicines Agency. Public summary of opinion on orphan designation: Cannabidivarin for treatment of fragile X syndrome. Available at: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/18/1977-public-summary-opinion-orphan-designation-
- US Food and Drug Administration. Orphan Drug Designations and Approvals. Available at: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/. Accessed on March 19, 2021.
- Brodie MJ, Czapinski P, Pazdera L, et al. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res 2021;6(6):528-536. PubMed
- Hurley EN, Ellaway CJ, Johnson AM, et al. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia 2022;63(7):1736-1747. PubMed
This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC
Cannabidivarin (cbdv): Common Questions
What is Cannabidivarin (cbdv) used for, and does it work?
Does Cannabidivarin (cbdv) interact with prescription medications?
How are Cannabidivarin (cbdv) interactions rated?
Is it safe to take Cannabidivarin (cbdv) with my medications?
Where does this Cannabidivarin (cbdv) interaction information come from?
What is CBDV used for?
Will CBDV get me high?
Is CBDV the same as CBD?
Is CBDV safe to take during pregnancy or breastfeeding?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Have a question about Cannabidivarin (cbdv)?
Our pharmacists answer your medication & supplement questions — free.